[
1. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122-30.
]Search in Google Scholar
[
2. Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. J Pregnancy. 2012;586578.10.1155/2012/586578340317722848831
]Search in Google Scholar
[
3. Prakash J, Ganiger VC. Acute Kidney Injury in Pregnancy-specific Disorders. Indian J Nephrol. 2017;27(4):258-70.10.4103/0971-4065.202406551482128761227
]Search in Google Scholar
[
4. Palacios de Franco Y, Velazquez K, Segovia N. Urinary podocalyxin as a marker of preeclampsia in a Hispanic population. Int J Physiol Pathophysiol Pharmacol. 2014;6(2):115-24.
]Search in Google Scholar
[
5. Assady S. et al. New Insights into podocyte biology in glomerular health and disease. J Am Soc Nephrol. 2017;28(6):1707-15.10.1681/ASN.2017010027546180728404664
]Search in Google Scholar
[
6. Nielsen JS, McNagny KM. The role of podocalyxin in health and disease. J Am Soc Nephrol. 2009;20(8):1669-76.10.1681/ASN.200807078219578008
]Search in Google Scholar
[
7. Goulopoulou S. Vascular endothelium: a potential source of podocalyxin in serum from pregnancies with preeclampsia. J Hypertens. 2017;35(11):2176-7.10.1097/HJH.000000000000146828953590
]Search in Google Scholar
[
8. Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D: Endothelial cell membranes contain podocalyxin: The major sialoprotein of visceral glomerular epithelial cells. J Cell Biol. 1986;102:484–91.10.1083/jcb.102.2.48421140823511072
]Search in Google Scholar
[
9. Sassetti C, Tangemann K, Singer MS, Kershaw DB, Rosen SD: Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: Parallels to CD34. J Exp Med. 1998;187:1965–75.10.1084/jem.187.12.196522123659625756
]Search in Google Scholar
[
10. Hara M, Yamagata K, Tomino Y, et al. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia. 2012;55(11):2913-19.10.1007/s00125-012-2661-7346437122854890
]Search in Google Scholar
[
11. Camici M. Urinary detection of podocyte injury. Biomed Pharmacother. 2007;61(5):245-9.10.1016/j.biopha.2006.12.00917532599
]Search in Google Scholar
[
12. Craici IM, Wagner SJ, Weissgerber TL, Grande JP, Garovic VD. Advances in the pathophysiology of preeclampsia and related podocyte injury. Kidney Int. 2014;86(2):275-85.10.1038/ki.2014.17411780624573315
]Search in Google Scholar
[
13. Biarc J, Simon R, Fonbonne C, Léonard JF, Gautier JC, Pasquier O, et al. Absolute quantification of podocalyxin, a potential biomarker of glomerular injury in human urine, by liquid chromatography-mass spectrometry. J Chromatogr A. 2015;1397:81-5.10.1016/j.chroma.2015.04.00325920963
]Search in Google Scholar
[
14. Kwon SH, Woollard JR, Saad A, Garovic VD, Zand L, Jordan KL, et al. Elevated urinary podocyte-derived extracellular microvesicles in renovascular hypertensive patients. Nephrol Dial Transplant. 2017;32(5):800-7.
]Search in Google Scholar
[
15. Martineau T, Boutin M, Côté AM, Maranda B, Bichet DG, Auray-Blais C. Tandem mass spectrometry analysis of urinary podocalyxin and podocin in the investigation of podocyturia in women with preeclampsia and Fabry disease patients. Clin Chim Acta. 2019;495:67-75.10.1016/j.cca.2019.03.161530898510
]Search in Google Scholar
[
16. Ylbe Palacios de F, Velazquez K, Segovia N, Sandoval G, Gauto E. Long term follow up of biomarkers of podocyte damage and renal function in patients with and without preeclampsia. Braz J Nephrol. 2018;40(4):339-43.10.1590/2175-8239-jbn-3941653400529782634
]Search in Google Scholar
[
17. Chen Q, Wang Y, Li Y, Zhao M, Nie G. Serum podocalyxin is significantly increased in early-onset preeclampsia and may represent a novel marker of maternal endothelial cell dysfunction. J Hypertens. 2017;35(11):2287-94.10.1097/HJH.000000000000146128665887
]Search in Google Scholar
[
18. Mansilla M, Wang Y, Hyett J, da Silva Costa F, Nie G. Serum podocalyxin for early detection of preeclampsia at 11–13 weeks of gestation. Placenta. 2018;71:13-15.10.1016/j.placenta.2018.09.00930415742
]Search in Google Scholar
[
19. Üstünyurt E, Çift T, Özdemir H, Temur M, Şimşek D, Budak Y. Podocalyxin levels in preeclampsia and relationship with severity of disease. Ann Clin Anal Med. 2020;11(3): S279-83.10.4328/ACAM.20196
]Search in Google Scholar
[
20. Amin A, Abou-Taleb H, Gamal M, Thabet M, Azoz N, Abbas A. Evaluation of Podocalyxin level in preeclampsia with severe features‘ patients: a cross-sectional study. Int J Reprod Contracept Obstet Gynecol. 2019;8(8):3255-8.10.18203/2320-1770.ijrcog20193545
]Search in Google Scholar
[
21. Dimitrakova E, Kostov I. Studies on the level of pro-inflammatory cytokines IIL-1a, IL-1b, IL-6, TNF-a in pregnant women with acute pyelonephritis. Akush Ginekol. 2011;50(2):3-6.
]Search in Google Scholar
[
22. Dimitrakova ED, Dimitrakov JD, Karumanchi SA, Pehlivanov BK, Milchev NP, Dimitrakov DI Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia. Folia Med. 2004;46(1):19-21.
]Search in Google Scholar
[
23. Dimitrakova E, Milchev N, Dimitrakov D, Batashki I, Gŭrova A. Placental angiogenic factors. Essentials and clinical significance in preeclampsia. Akush Ginekol. 2006;45(3):52-8.
]Search in Google Scholar
[
24. Dimitrakova E, Milchev N, Batashki I, Karumanchi SA. Cause-effect relatioships between circulating placental angiogenic proteins and serum IL-2, IL-6 and IL-10 levels in pregnant women with preeclampsia. Akush Ginekol. 2007;46(9):4-8.
]Search in Google Scholar
